Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2

Mol Cell Biol. 2002 Jan;22(1):270-85. doi: 10.1128/MCB.22.1.270-285.2002.


The four receptor tyrosine kinases of the ErbB family play essential roles in several physiological processes and have also been implicated in tumor generation and/or progression. Activation of ErbB1/EGFR is mainly triggered by epidermal growth factor (EGF) and other related ligands, while activation of ErbB2, ErbB3, and ErbB4 receptors occurs by binding to another set of EGF-like ligands termed neuregulins (NRGs). Here we show that the Erk5 mitogen-activated protein kinase (MAPK) pathway participates in NRG signal transduction. In MCF7 cells, NRG activated Erk5 in a time- and dose-dependent fashion. The action of NRG on Erk5 was dependent on the kinase activity of ErbB receptors but was independent of Ras. Expression in MCF7 cells of a dominant negative form of Erk5 resulted in a significant decrease in NRG-induced proliferation of MCF7 cells. Analysis of Erk5 in several human tumor cell lines indicated that a constitutively active form of this kinase was present in the BT474 and SKBR3 cell lines, which also expressed activated forms of ErbB2, ErbB3, and ErbB4. Treatments aimed at decreasing the activity of these receptors caused Erk5 inactivation, indicating that the active form of Erk5 present in BT474 and SKBR3 cells was due to a persistent positive stimulus originating at the ErbB receptors. In BT474 cells expression of the dominant negative form of Erk5 resulted in reduced proliferation, indicating that in these cells Erk5 was also involved in the control of proliferation. Taken together, these results suggest that Erk5 may play a role in the regulation of cell proliferation by NRG receptors and indicate that constitutively active NRG receptors may induce proliferative responses in cancer cells through this MAPK pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Active Transport, Cell Nucleus / physiology
  • Antineoplastic Agents / pharmacology
  • Breast Neoplasms
  • Butadienes / pharmacology
  • Cell Division / physiology
  • Enzyme Inhibitors / pharmacology
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / metabolism*
  • Female
  • Humans
  • MAP Kinase Signaling System / physiology*
  • Microscopy, Fluorescence
  • Mitogen-Activated Protein Kinase 7
  • Mitogen-Activated Protein Kinases / genetics
  • Mitogen-Activated Protein Kinases / metabolism*
  • Neuregulins / genetics
  • Neuregulins / metabolism*
  • Nitriles / pharmacology
  • Phosphorylation
  • Phthalimides / pharmacology
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / metabolism*
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / metabolism
  • Tumor Cells, Cultured


  • 4,5-bis(4-fluoroanilino)phthalimide
  • Antineoplastic Agents
  • Butadienes
  • Enzyme Inhibitors
  • Neuregulins
  • Nitriles
  • Phthalimides
  • Recombinant Fusion Proteins
  • U 0126
  • ErbB Receptors
  • Receptor, ErbB-2
  • Mitogen-Activated Protein Kinase 7
  • Mitogen-Activated Protein Kinases